Current Clinical Trials
To advance knowledge, identify the most effective care and help future patients, the Edwards Comprehensive Cancer Center maintains an active clinical trials program and maintains a listing of the clinical trials that are currently available.
If you have questions about whether a clinical trial is an option for you, please contact Keshia Bowen, RN at 304.399.6521, Clinical Research. For more information about Pediatric Clinical Trials, please contact Christina Cole at 304.399.6638.
| Code | Description | Type |
|---|---|---|
| A011801 | The compassher2 trials (comprehensive use of pathologic response assessment to optimize therapy in her2-positive breast cancer): compassher2 residual disease (rd), a double-blinded, phase III randomized trial of t-dm1 and placebo compared with t-dm1 and tucatinib | Breast Cancer |
| A012103 | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy | Breast Cancer |
| A021806 | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | Gastrointestinal Cancer |
| A081801 | Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO | Lung Cancer |
| A151216 | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). | Lung Cancer |
| A212102 | Blinded Reference Set For Multicancer Early Detection Blood Tests 9/18/23 8/1/2022 0/1755 0 0 X | |
| CG03-EOC1 | Standard Chemotherapy versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | Gynecologic Cancer |
| EA6141 | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma. | Melanoma |
| EAY-191 | EAY191-Molecular Analysis for Combination Therapy Choice (ComboMATCH) | Gynecologic Cancer |
| EAY191-N4 | A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial | Gynecologic Cancer |
| LungMAP | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) | Lung Cancer |
| Metabolomic | Metabolomic signatures of human LIVER function & disease | Gastrointestinal Cancer |
| NRG-BR007 | A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score =18 Breast Cancer | Breast Cancer |
| NRG-GU011 | A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) | Genitourinary Cancer |
| NRG-LU008 | Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer Stage II or III, known PD-L1 status, primary tumor and at least 1 nodal met |
Lung Cancer |
| S1900E | A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) | Lung Cancer |
| S1900G - | A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) Stage IV or recurrent |
Lung Cancer |
| S1900K | A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) ( NCT06031688) Stage IV or recurrent/ MET Exon 14 Skipping | Lung Cancer |
| S1914 | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC | Lung Cancer |
| S1937 | A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | Genitourinary Cancer |
| S2010 | A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN) | Breast Cancer |
| S2013 | IMMUNE CHECKPOINT INHIBITOR TOXICITY (I-CHECKIT): A PROSPECTIVE OBSERVATIONAL STUDY *Temporarily closed to accrual as of 05/06/2024* |
|
| S2302 | Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer | Lung Cancer |
| Code | Description | Type |
|---|---|---|
| AALL1631/ NCT#03007147 | PH + ALL | Leukemia/Lymphoma |
| AALL1732/ NCT#03959085 | High Risk B-ALL | Leukemia/Lymphoma |
| AREN1921/NCT#04322318 | Newly Diagnosed Diffuse Anaplastic Wilms Tumor | Rare Tumors |